BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31309709)

  • 1. siRNA Targeting and Treatment of Gastrointestinal Diseases.
    Chevalier R
    Clin Transl Sci; 2019 Nov; 12(6):573-585. PubMed ID: 31309709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
    Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
    Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
    Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
    Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
    Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
    Kim B; Park JH; Sailor MJ
    Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain.
    Haroon MM; Dar GH; Jeyalakshmi D; Venkatraman U; Saba K; Rangaraj N; Patel AB; Gopal V
    J Control Release; 2016 Apr; 228():120-131. PubMed ID: 26948382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
    Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
    Jackson MA; Werfel TA; Curvino EJ; Yu F; Kavanaugh TE; Sarett SM; Dockery MD; Kilchrist KV; Jackson AN; Giorgio TD; Duvall CL
    ACS Nano; 2017 Jun; 11(6):5680-5696. PubMed ID: 28548843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
    Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
    Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional peptides for siRNA delivery.
    Tai W; Gao X
    Adv Drug Deliv Rev; 2017 Feb; 110-111():157-168. PubMed ID: 27530388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.
    Gujrati M; Vaidya A; Lu ZR
    Bioconjug Chem; 2016 Jan; 27(1):19-35. PubMed ID: 26629982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?
    Hossian AKMN; Mackenzie GG; Mattheolabakis G
    Nanomedicine (Lond); 2019 Nov; 14(21):2873-2889. PubMed ID: 31735124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.